Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study
This nationwide study demonstrated a low incidence of positive SNs and minimal likelihood of significant clinical outcomes following SLNB. Given the high NNT to be eligible for adjuvant immunotherapy, SLNB may no longer be justified for pT1b melanoma. For patients with pT2a melanoma, SLNB should be considered carefully, balancing limited clinical benefits against potential risks.
Authors
- Astrid A.M. van der Veldt (ORCID: https://orcid.org/0000-0003-0446-1907)
- Petra Verhoef (ORCID: https://orcid.org/0000-0002-6927-6182)
- Robert C Stassen
- Dirk J. Grünhagen (ORCID: https://orcid.org/0000-0001-8293-6002)
- Loes M. Hollestein (ORCID: https://orcid.org/0000-0001-8922-6791)
- Antonius W Schurink
Institutions
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1016/j.ejca.2025.115365
- Citations
- 5
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.23